Canrong Wu

4.0k total citations · 1 hit paper
28 papers, 2.5k citations indexed

About

Canrong Wu is a scholar working on Molecular Biology, Cancer Research and Infectious Diseases. According to data from OpenAlex, Canrong Wu has authored 28 papers receiving a total of 2.5k indexed citations (citations by other indexed papers that have themselves been cited), including 20 papers in Molecular Biology, 7 papers in Cancer Research and 4 papers in Infectious Diseases. Recurrent topics in Canrong Wu's work include Cancer, Hypoxia, and Metabolism (6 papers), Receptor Mechanisms and Signaling (5 papers) and SARS-CoV-2 and COVID-19 Research (4 papers). Canrong Wu is often cited by papers focused on Cancer, Hypoxia, and Metabolism (6 papers), Receptor Mechanisms and Signaling (5 papers) and SARS-CoV-2 and COVID-19 Research (4 papers). Canrong Wu collaborates with scholars based in China, United States and Netherlands. Canrong Wu's co-authors include Hua Li, Lixia Chen, Mengzhu Zheng, Yueying Yang, Yang Xu, Yali Wang, Xingzhou Li, Yang Liu, Qiqi Wang and Wu Zhong and has published in prestigious journals such as Nature, Proceedings of the National Academy of Sciences and Nature Communications.

In The Last Decade

Canrong Wu

26 papers receiving 2.5k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Analysis of therapeutic targets for SARS-CoV-2 and discovery of potential drugs by computational methods

2020 1.7k citations Canrong Wu, Yang Liu et al. Acta Pharmaceutica Sinica B profile →

Peers

Countries citing papers authored by Canrong Wu

Since Specialization

Citations

This map shows the geographic impact of Canrong Wu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Canrong Wu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Canrong Wu more than expected).

Fields of papers citing papers by Canrong Wu

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Canrong Wu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Canrong Wu. The network helps show where Canrong Wu may publish in the future.

Co-authorship network of co-authors of Canrong Wu

This figure shows the co-authorship network connecting the top 25 collaborators of Canrong Wu. A scholar is included among the top collaborators of Canrong Wu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Canrong Wu. Canrong Wu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Structural insights into antagonist recognition by the vasopressin V2 receptor 2025 ·Nature Communications ·(unknown), Hongli Liu, Chongzhao You, Yixiao Zhang, Youwei Xu, (unknown), Canrong Wu, (unknown), Yu-Ling Yin, Kai Wu, (unknown), Hong Sun, Yuan Si, Yangxia Tan, Wanchao Yin, H. Eric Xu, Dong Guo, Yi Jiang	0
2	Structural insights into selective and dual antagonism of EP2 and EP4 prostaglandin receptors 2025 ·The EMBO Journal ·(unknown), (unknown), (unknown), Kaichun Wu, Wen Hu, Xinheng He, Gaoming Wang, Canrong Wu, H. Eric Xu	0
3	Structural insights into the activation of the human prostaglandin E ₂ receptor EP1 subtype by prostaglandin E ₂ 2025 ·Proceedings of the National Academy of Sciences ·Xue Meng, Yang Li, (unknown), Kai Wu, Wen Hu, Canrong Wu, H. Eric Xu, Youwei Xu	2
4	Molecular mechanisms of urate transport by the native human URAT1 and its inhibition by anti-gout drugs 2025 ·Cell Discovery ·Canrong Wu, Yong Zhang, (unknown), (unknown), Antao Dai, (unknown), (unknown), Xuemei Yang, Xinheng He, Qingning Yuan, Wen Hu, Youwei Xu, Ming‐Wei Wang, Yi Jiang, Dehua Yang, H. Eric Xu	2
5	Molecular recognition and activation of the prostacyclin receptor by anti-pulmonary arterial hypertension drugs 2024 ·Science Advances ·(unknown), (unknown), (unknown), Youwei Xu, Wen Hu, Yi Jiang, Chen Chen, Dao Wen Wang, H. Eric Xu, Canrong Wu	7
6	Molecular basis of lipid and ligand regulation of prostaglandin receptor DP2 2024 ·Proceedings of the National Academy of Sciences ·(unknown), Youwei Xu, Li Hou, Xinheng He, Yang Li, (unknown), Xue Meng, (unknown), Yanli Wu, (unknown), (unknown), Wen Hu, Qingning Yuan, Kai Wu, Xi Cheng, Yiguo Jiang, Xia Yu, H. Eric Xu, Canrong Wu	5
7	Structural basis for recognition of 26RFa by the pyroglutamylated RFamide peptide receptor 2024 ·Cell Discovery ·(unknown), Shimeng Guo, Youwei Xu, Xin Li, Canrong Wu, Xinheng He, (unknown), Wenwen Xin, Heng Zhang, Wen Hu, Yu-Ling Yin, Tianwei Zhang, Kaichun Wu, Qingning Yuan, H. Eric Xu, Xin Xie, Yi Jiang	3
8	Dimerization and antidepressant recognition at noradrenaline transporter 2024 ·Nature ·(unknown), Yu-Ling Yin, Antao Dai, Tianwei Zhang, Chao Zhang, Canrong Wu, (unknown), Xinheng He, (unknown), (unknown), Qingning Yuan, Ming‐Wei Wang, Dehua Yang, H. Eric Xu, Yi Jiang	18
9	Ligand-induced activation and G protein coupling of prostaglandin F2α receptor 2023 ·Nature Communications ·Canrong Wu, Youwei Xu, Qian He, Dianrong Li, Jia Duan, Changyao Li, Chongzhao You, (unknown), Weiliang Fan, Yi Jiang, H. Eric Xu	12
10	Structure genomics of SARS-CoV-2 and its Omicron variant: drug design templates for COVID-19 2022 ·Acta Pharmacologica Sinica ·Canrong Wu, Wanchao Yin, Yi Jiang, H. Eric Xu	77
11	Rational Design and Synthesis of Novel Dual PROTACs for Simultaneous Degradation of EGFR and PARP 2021 ·Journal of Medicinal Chemistry ·Mengzhu Zheng, (unknown), Xiaoxia Gu, Yali Wang, Canrong Wu, Qingzhe Zhang, Wancong Wang, Yang Liu, Yu Liu, (unknown), Lixia Chen, Yirong Zhou, Hua Li	145
12	3-Phosphoglycerate dehydrogenase: a potential target for cancer treatment 2021 ·Cellular Oncology ·Mingxue Li, Canrong Wu, Yueying Yang, Mengzhu Zheng, (unknown), Jinhui Wang, Lixia Chen, Hua Li	29
13	Novel PROTACs for degradation of SHP2 protein 2021 ·Bioorganic Chemistry ·Mengzhu Zheng, Yang Liu, Canrong Wu, Kaiyin Yang, Qiqi Wang, Yirong Zhou, Lixia Chen, Hua Li	58
14	Furin: A Potential Therapeutic Target for COVID-19 2020 ·iScience ·Canrong Wu, Mengzhu Zheng, Yueying Yang, Xiaoxia Gu, Kaiyin Yang, (unknown), Yang Liu, Qingzhe Zhang, Peng Zhang, Yali Wang, Qiqi Wang, Yang Xu, Yirong Zhou, Yonghui Zhang, Lixia Chen, Hua Li	141
15	Discovery of an Orally Active Small-Molecule Tumor Necrosis Factor-α Inhibitor 2020 ·Journal of Medicinal Chemistry ·Weiguang Sun, Yanli Wu, Mengzhu Zheng, Yueying Yang, Yang Liu, Canrong Wu, Yirong Zhou, Yonghui Zhang, Lixia Chen, Hua Li	23
16	Analysis of therapeutic targets for SARS-CoV-2 and discovery of potential drugs by computational methods breakdown → 2020 ·Acta Pharmaceutica Sinica B ·Canrong Wu, Yang Liu, Yueying Yang, Peng Zhang, Wu Zhong, Yali Wang, Qiqi Wang, Yang Xu, (unknown), Xingzhou Li, Mengzhu Zheng, Lixia Chen, Hua Li	1653
17	Novel selective hexokinase 2 inhibitor Benitrobenrazide blocks cancer cells growth by targeting glycolysis 2020 ·Pharmacological Research ·Mengzhu Zheng, Canrong Wu, Kaiyin Yang, Yueying Yang, Yang Liu, Suyu Gao, Qiqi Wang, Chen Li, Lixia Chen, Hua Li	72
18	Synthesis of novel andrographolide beckmann rearrangement derivatives and evaluation of their HK2-related anti-inflammatory activities 2019 ·European Journal of Medicinal Chemistry ·Wancong Wang, Yanli Wu, Kaiyin Yang, Canrong Wu, (unknown), Hua Li, Lixia Chen	26
19	Physapubescin I from husk tomato suppresses SW1990 cancer cell growth by targeting kidney-type glutaminase 2019 ·Bioorganic Chemistry ·Kaiyin Yang, Canrong Wu, Mengzhu Zheng, (unknown), Xingzhou Li, Lixia Chen, Hua Li	19
20	New natural inhibitors of hexokinase 2 (HK2): Steroids from Ganoderma sinense 2018 ·Fitoterapia ·(unknown), Kaiyin Yang, Canrong Wu, Suyu Gao, Penghe Wang, Lixia Chen, Hua Li	55

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact